PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment of advanced solid tumors. To find predictive biomarkers of drug sensitivity, we screened a diverse panel of 87 cancer cell lines for growth inhibition upon PF-03814735 treatment. Small cell lung cancer (SCLC) and, to a lesser extent, colon cancer lines were very sensitive to PF-03814735. The status of the Myc gene family and retinoblastoma pathway members significantly correlated with the efficacy of PF-03814735. Whereas RB1 inactivation, intact CDKN2A/p16, and normal CCND1/Cyclin D1 status are hallmarks of SCLC, activation or amplification of any of the three Myc genes (MYC, MYCL1, and MYCN) clearly differentiated cell line sensitivity within the SCLC panel. By contrast, we found that expression of Aurora A and B were weak predictors of response. We observed a decrease in histone H3 phosphorylation and polyploidization of sensitive lines, consistent with the phenotype of Aurora B inhibition. In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc-driven tumors. Altogether our results suggest that SCLC and other malignancies driven by the Myc family genes may be suitable indications for treatment by Aurora B kinase inhibitors. Mol Cancer Ther; Ó2012 AACR.
Introduction
Aneuploidy, one of the key features of cancer, is often linked to abnormalities in the regulation of mitotic cell division (1) . Targeting dividing cells by inhibiting mitotic processes and their regulation represents a promising approach to cancer treatment (2) , and several druggable targets have been identified as important mitotic regulators (3, 4) .
The Aurora family of serine/threonine kinases are key regulators of mitosis and are frequently overexpressed in cancer (5) . Aurora kinase A (AURKA) plays a key role in centrosome maturation, whereas Aurora kinase B (AURKB) regulates chromatid segregation during mitosis and cytokinesis. On the molecular level, the phenotypic manifestation of Aurora A and B inhibition differs. AURKA inhibition is characterized by centrosome separation defects, a monopolar spindle, and delayed mitotic entry. The phenotype of Aurora B inhibition, on the other hand, includes decreased histone H3 phosphorylation as well as endomitosis, with increased ploidy followed by apoptosis (6) (7) (8) . The oncogenic role of the remaining Aurora kinase C is less understood.
Over a dozen small molecule Aurora kinase inhibitors have entered clinical development (9) . Although confirmed responders seem to be rare, several patients with stable disease have been reported (9) . Given the relatively low response, reliable predictive biomarkers for patient selection are critical for clinical success.
In this study, we profiled the activity of the AURKA and AURKB inhibitor PF-03814735 (10) in a panel of diverse carcinoma lines. We found that small cell lung cancer (SCLC) lines in general, and Myc family-driven, RB1/retinoblastoma null models in particular, have increased sensitivity to PF-03814735. The observed decrease in histone H3 phosphorylation and polyploidization of sensitive lines is consistent with an Aurora B inhibition phenotype. Implications for tumor indication and patient selection are discussed.
Materials and Methods
Cell lines, cell cultures, and reagents PF-03814735 was tested in vitro in a panel of 87 cancer lines derived from human lung (small cell and non-small cell), breast, and colorectal tumors. Tumor cells were obtained from American Type Culture Collection (ATCC), or DSMZ (Braunschweig, Germany). Cells lines were authenticated by the supplier (ATCC and DSMZ) and kept in culture for maximum of 3 months. Cells were grown in appropriate culture media as recommended by the suppliers, including RPMI-1640, MEM, Dulbecco's Modified Eagle's Medium (DMEM), and DMEM-F12 (all from Invitrogen). Supplements included HEPES buffer, sodium pyruvate, nonessential amino acids, Pen-Strep, ITS, glutamine (all from Invitrogen) and FBS, 5% to 20% (SAFC Biosciences). Some of the SCLC lines were grown in ACL-4 medium as described in online material of ATCC (supplements from Sigma-Aldrich).
Proliferation assays
Cells were seeded into 96-well tissue culture plates (Costar 3997; Corning) and incubated at 37 C in 5% CO 2 in humidified air. Compounds were dissolved in dimethyl sulfoxide or PBS, diluted in polypropylene wells (Costar 3359), and added to cell cultures with the aid of a Biomek workstation (Beckman-Coulter). Compounds were added 24 hours after seeding and plates were further incubated until cultures reached about 80% confluence, usually 3 to 7 days. Cell growth was monitored with either a fluorescence readout from resazurin (Sigma-Aldrich), 0.01% final concentration, or luminescence from a Cell Titer-Glo kit (Promega), which was analyzed with an EnVision 2104 Multilabel Reader (Perkin-Elmer). Cell counts were adjusted by subtracting the average of the baseline cell counts from untreated cells assessed one day after cell seeding, and IC 50 values were computed by fitting the fluorescence and concentration values to nonlinear curves, as implemented by the drc add-in to the open source language R (11).
Mutation data, gene amplification, and expression data
The mutation status of the cell lines was determined from the COSMIC database (12), supplemented with custom OncoCarta (Sequenom) profiling. Baseline whole-genome expression and copy number variation in selected cell lines were obtained from public resources and complemented with internal profiling on HG-U133 Plus 2.0 arrays (Affymetrix) and SNP 6.0 arrays (Affymetrix) according to the manufacturer's protocols. Publicly available reference profiles of cancer cell lines on the same platforms were obtained from the Welcome Trust Sanger Institute's CONAN dataset (COpy Number ANalysis, http://www.sanger.ac.uk/ genetics/CGP/CopyNumberMapping/Affy_SNP6.shtml), GlaxoSmithKline (https://cabig.nci.nih.gov/caArray_ GSKdata/), and Genentech (GSE10843). All the new array data were deposited into GEO (GSE34211). For gene expression, we first excluded all arrays with NUSE score more than 1.05 and then normalized by GC-RMA (13) using the gcrma Bioconductor package. When multiple arrays were available, we used the median of normalized values. The final data are available in Supplementary Table S1 . SNP 6.0 arrays were processed using the R based aroma.affymetrix methods. (ref. 14; http://www.aroma-project.org/). Arrays were ratioed versus a baseline profile of the average of the 128 females from the International HapMap Project (http:// www.affymetrix.com/estore/support/technical/sample_ data/genomewide_snp6_data.affx). Supplementary Table  S2 contains the summarized table of DNA alterations used in our analysis.
DNA copy number of Myc family (MYC, MYCN, and MYCL1) genes and mRNA expression levels of Myc and CDKN2A, CCND1, and RB1 genes were confirmed via TaqMan (Applied Biosystems). Manufacturer's assay codes are listed in Supplementary Table S3 . Copy number and expression were assessed using real-time PCR on an ABI Prism 7900 (Applied Biosystems) according to the manufacturer's protocol. Copy number was calculated from quadruplet reactions using ABI CopyCaller software, whereby the cycle threshold (C T ) of the target gene was normalized against the C T of an RNaseP reference assay. Gene copy number was calculated relative to nontumor reference genomic DNA (NA17317; Coriell Institute for Medical Research). mRNA expression was first normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the relative gene expression was calculated by subtracting the average delta C T of triplicate reactions to the median of the average delta C T across each tumor type. The C T values for both copy number and expression data are listed in Supplementary Table S4 .
Data analysis and statistical methods
DNA changes were summarized as follows: any change on the amino acid level was defined to be a mutation, whereas silent mutations were excluded from the analysis. Gene amplifications from whole-genome SNP 6.0 arrays were defined to be members of focally amplified chromosomal segments consisting of no more than 10 Mb containing at least 5 probes, each with a mean log 2 ratio equal or greater than 1. There was no size constraint on the length of the chromosomal deletion: segments were required to contain a minimum of 5 probes each with a mean log 2 less than À2.
Amplifications of the Myc family genes were validated by TaqMan PCR. Cell lines with more than 10 copies (as measured by TaqMan PCR) of any Myc family member (MYC, MYCN, and MYCL1) were defined to be Myc family amplified. Cell lines were defined to overexpress the Myc family if the highest expressing Myc family member had relative expression more than one SD above the median of nonamplified lines.
The nonparametric Wilcoxon or Kruskal-Wallis rank tests as well as Fisher's exact binomial test, as implemented in R, were used to correlate in vitro growth inhibition data and categorical predictors such as the presence of genetic changes and tissue of origin. Spearman's rank correlation was used for continuous RNA expression profiles. The contributions of tissue origin to the observed correlations were tested using ANCOVA and ANOVA tests from the R lm module after factoring the tissue effect.
The presence of a predictive signature was tested using BRB-ArrayTools v4.1 (15) . We split the samples into 2 categories: sensitive, defined as having IC 50 < 100 nmol/L, and resistant, with IC 50 >3 mmol/L, and removed the lines with intermediate values of IC 50 . We filtered out control probesets, noninformative probesets whose expression values deviate at least 1.5-fold in either direction from the median value in fewer than 20% of the cell lines, and those probesets with more than 50% of their data missing. Probesets with univariate misclassfication rate below 0.2 were used for class prediction using the diagonal linear discriminant analysis (DLDA) model. The leave-one-out cross-validation method was used to estimate the misclassification rate.
Western immunoblots
For Western immunoblots, cells were first washed in PBS and then lysed/protein extracted for 1 hour at 0 C in cell extraction buffer (Invitrogen) supplemented with phosphatase inhibitors 2 and 3, phenylmethylsulfonylfluoride, (Sigma-Aldrich), and complete protease inhibitor cocktail (Roche), before centrifugation at 14,000 Â g for 10 minutes. Supernates were assayed for protein content with BCA reagents (Pierce) to ensure uniform gel loading. Polyacrylamide gel samples were prepared in NuPAGE sample buffer supplemented with reducing agent (Invitrogen) and run on 4% to 12% Bis-tris NuPage gels (Invitrogen). Proteins were transferred to nitrocellulose membranes and immunoblotted for PARP (Cell Signaling 9542), MYC/C-Myc (Santa Cruz sc-40), MYCN/N-Myc (Cell Signaling 9405), or the loading control protein ezrin (Cell Signaling 3145), and imaged with SuperSignal West Pico (Pierce) with the aid of an Alpha Imager (Cell Biosciences). For the "washout" phase of the time course PF-03814735 was removed after 24 hours by centrifugation at 200 Â g followed by PBS washes before resuspension in fresh medium and further incubation. For the MYC protein decay curves, NCI-H82 cells were left untreated or were treated with 500 nmol/L PF-3814735 for 4 hours before removal of duplicate samples immediately before addition of 50 mg/mL cycloheximide and at several time points thereafter. MYC protein levels were estimated by densitometric analysis of MYC bands on immunoblots using the image analysis software AlphaEaseFC (Cell Biosciences).
Short interfering RNA transfection
Short interfering RNAs (siRNA) were transfected into NCI-H82 cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's reverse transfection protocol. Briefly, 18 pmol of siRNA (Dharmacon ON-TARGET plus Human MYC; Thermo Fisher) and 1.5 mL of Lipofectamine RNAiMAX were used to prepare RNAi duplex-Lipofectamine RNAiMAX complexes in 100 mL of Opti-MEM I medium (Invitrogen) in 24-well plates. After 20 minutes, 8 Â 10 4 cells in 500 mL of complete culture medium were added to each well. Cells were either transferred to 96-well plates 24 hours after transfection for proliferation assays (as previously described), or were pooled in groups of three, 90 hours after transfection, and lysed for Western immunoblots to monitor MYC knockdown.
Flow cytometry
Cell samples for flow cytometry were washed in PBS, fixed by dropwise addition of cold methanol, incubated 20 minutes at 0 C, and stored for up to a week in 50% methanol/50% PBS. Cells were stained for phosphohistone H3 (Alexa 488-conjugated anti-histone H3 antibody; Cell Signaling 9708) in 50 mL wash buffer consisting of 2% bovine serum albumin, 0.5% Tween 20, and 1 mmol/L EDTA (all Sigma-Aldrich) in PBS. The cells were then washed and resuspended in saline containing 50 mg/mL propidium iodide and 30 u/mL RNase A (both Sigma-Aldrich). The cells were analyzed on a FACSCalibur flow cytometer (BD Biosciences) before population discrimination with WinList and ModFit software (Verity).
Human tumor xenograft studies
We selected 2 SCLC lines for further testing in vivo. For xenograft studies, 2 Â 10 6 tumor cells in 50% Matrigel were implanted in the right flank of female nu/nu mice (Charles River) housed in microisolator cages and provided with food and water ad libitum. All procedures were conducted in compliance with Pfizer Institutional Animal Care and Use Committee guidelines. Tumors were allowed to grow to a size of about 200 mm 3 before randomization into treatment groups of 5 to 10 animals each. Animals were treated per orally with PF-03814735 prepared in 12.5% ethanol, 12.5% cremophor (Sigma-Aldrich) in saline at doses and schedules shown below. Tumors were measured with calipers in 2 dimensions and their volumes were calculated according to the formula (length Â width 2 ) Â 0.5. Tumor measurements and body weights were taken twice per week until the tumors reached a size of about 2,000 mm 3 , at which point the mice were sacrificed. Tumor growth delay and cell kill analyses were done as described previously (16) .
Results

PF-03814735 activity in vitro
We tested PF-03814735 activity in vitro in a diverse panel of 87 lung, colon, and breast tumors lines. Activity ranged from sensitive cell lines with low double-digit nmol/L IC 50 to resistant lines with IC 50 greater than 10 mmol/L (Fig. 1A ). Significant tissue-specific differences in sensitivity were observed (KruskalWallis, P < 0.0001): SCLC and colon lines were on average more sensitive to PF-03814735 than non-SCLC and breast models (Fig. 1B) . Because the sensitivity profile was not bimodal, we carried out initial predictive biomarker analyses using nonparametric rank tests without dividing models into sensitive and resistant categories.
First, we compared the compound activity measured by IC 50 to the genetic status of selected key cancer drivers (Fig. 1C) , as measured by whole-genome copy number arrays and somatic mutation data (see Materials and Methods). No correlation was observed between the rare amplifications of Aurora kinase genes and sensitivity. We noticed increasing sensitivity of lines with amplified MYCL1/L-Myc (Kruskal-Wallis, P ¼ 0.024) and a trend for MYC/c-Myc (not significant), and confirmed these results by TaqMan PCR data (Fig. 1D) . We also found correlations between the antiproliferative activity of PF-03814735 and several RB1 pathway genes. RB1/retinoblastoma mutations/deletions (P ¼ 0.023) were positively correlated with response; amplifications of CCND1/cyclin D1 (P ¼ 0.041) and mutations/deletions of CDKN2A/p16
INK4A (P ¼ 0.027) were associated with resistance. Figure 1E shows mRNA expression of the Aurora kinase family, Myc family, and key RB1 pathway genes measured by TaqMan PCR. We found only weak correlations with Aurora kinases: the weak positive correlation between AURKA mRNA expression and IC 50 (Spearman's rank R ¼ 0.27; P ¼ 0.012) indicates increased expression of this gene in cell lines resistant to the inhibitor. By contrast, AURKB expression was weakly (Spearman's rank R ¼ À0. CAMA1  HCC1143  HCC1419  HCC2935  NCIH2405  SKBR3  ZR751  HCC1954  NCIH1651  NCIH226  T47D  NCIH747  NCIH345  DLD1  NCIH1666  BT20  NCIH196  NCIH1437  LS123  NCIH2347  BT474  CACO2  HCC1806  NCIH841  NCIH647  SKMES1  NCIH1650  NCIH1755  NCIH23  BT549  NCIH1975  CALU6  A549  NCIH1838  HCC827  MCF7  NCIH441  HCC1395  NCIH520  NCIH1703  ZR7530  SW480  NCIH526  NCIH146  HCC1569  MCF12A  MCF10  NCIH209  RKO  HCC70  LS513  NCIH1963  HCC1187  T84  COLO205  LS1034  NCIH69  NCIH187  HCT116  NCIH1184  NCIH508  SNUC1  HCC38  NCIN592  SW403  NCIH378  NCIH446  LS174T  NCIH82  NCIH2107  SKCO1  NCIN417  NCIH889  SW48  MX1  NCIH524  NCIH716  MDAMB157  MDAMB361  MDAMB231  MDAMB415  MDAMB453  MDAMB436  MDAMB468  NCIH249 INK4A (R ¼ À0.31; P ¼ 0.003) were on average more sensitive. Contrary to the DNA data, however, no association was found between the RB1 mRNA level and PF-03814735 efficacy.
Given the significant association of PF-03814735 activity with the cell line origin (see above), one of the potentially confounding factors in our analysis is nonrandom alterations of genes in different tissues. Indeed, amplification of Myc loci and RB1 inactivation are hallmarks of SCLC (17) (18) (19) (20) . When controlled for the tumor type in ANCOVA (see Materials and Methods), the status of the Myc family genes and RB1 the pathway genes were no longer significant.
To further elucidate the confounding role of cell line origin, we specifically analyzed Myc family amplification and expression on sensitivity of SCLC cell lines (Table 1) . We found that no resistant models had Myc family amplifications. The difference in IC 50 values was significant between the lines with high amplification and those with normal/low copy number (P ¼ 0.001; Wilcoxon rank test). Interestingly, even low-level amplification of any Myc family member is sufficient to sensitize some cell lines to PF-03814735 inhibition in vitro. Taken together, we concluded that within the SCLC line panel, Myc gene activation sensitized lines to PF-03814735. We were unable to test the role of the RB1 pathway status in SCLC lines, as all lines were RB1-null.
Activation of individual Myc family genes in our cell line panel was mutually exclusive (Fig. 1C-E, Table 1 ). Therefore, we combined Myc gene activity into a summarized value in an effort to improve the predictive power. Indeed, as shown in Fig. 2A and B, the differences between lines with amplification or overexpression of at least one Myc gene and the remaining lines became highly significant (Wilcoxon P ¼ 0.0018 and 0.000008 for amplified and overexpressed lines, respectively). However, there are several sensitive lines without any obvious Myc family activation and thus the combined status of Myc family genes do not fully explain the sensitivity profile. Figure 2C and D compare the predictive power of all the major binary predictors identified in this work (see the figure legend and Material and Methods for details). MYC and MYCL1 overexpression, MYCN and MYCL1 amplifications, RB1 deletions/mutations, SCLC origin, and activation of any Myc gene by amplification and overexpression were the best predictors of sensitivity measured by the odds ratio and average IC 50 . CCND1 amplifications and inactivations of p16 INK4A /CDKN2A were associated with cell line resistance. At the statistical significance level, the best predictors were activation of Myc family by We developed a gene expression classifier from whole-genome expression data. We split the samples into 2 categories: sensitive, defined as IC 50 < 100 nmol/L and resistant, with IC 50 >3 mmol/L, and removed lines with intermediate response. A total of 247 probesets with univariate misclassification rate below 0.2 were used for class prediction using DLDA. Leave-one-out cross-validation of the derived signature in our dataset correctly predicted 86% of all cell lines with 0.844 specificity and 0.875 sensitivity. The observed sensitivity signature requires validation in an independent set of samples. The full prediction model including the genes, weights, and threshold is described in the Supplementary Files.
MYC downregulation by siRNAs decreases cell sensitivity to PF-03814735
To further characterize the role of Myc genes in PF-03814735 sensitivity, we modulated MYC RNA in MYC-amplified NCI-H82 cells and compared with control cells (Fig. 3) . We used 2 different MYC-targeted siRNAs, one of which downregulated MYC expression. A strong knockdown of MYC resulted in complete inhibition of NCI-H82 proliferation (not shown) and thus we used only partially inhibited MYC. Even a modest downregulation of MYC expression by 31% was sufficient for the loss of sensitivity to PF-03814735, unlike the other siRNAs or controls that did not modulate MYC expression. Thus MYC expression both correlates with PF-03814735 sensitivity in a diverse panel of cell lines and is required for sustained inhibition by this compound in MYC-driven lines.
Phenotypic effects of PF-03814735 treatment
Because Aurora A has been shown to modulate MYCN protein stability and longevity in neuroblastoma cells (21) function of exposure to the Aurora kinase inhibitory activity of PF-03814735 at 2 concentrations. In addition, we immunoblotted for PARP and its cleavage product as a measure of apoptosis ( Supplementary Fig. 1SA-C) . Over a time course of 1 to 48 hours, plus a series of time points following the washout of inhibitor, MYC levels were unaffected by treatment with PF-03814735. There was little evidence of PARP cleavage during the first 48 hours of exposure to PF-03814735. We observed no difference in MYC protein stability or mRNA expression levels after PF-03814735 treatment (Supplementary Fig. S2 and S3 ), or by siRNA AURKA or AURKB inhibition (not shown).
Cells from these same time course experiments were stained for phospho-histone H3 (a substrate of Aurora B kinase) and DNA content, and analyzed by flow cytometry. Figure 4A depicts an example dot plot illustrating the gating strategy used to estimate the fraction of phosphohistone H3-positive cells. Cells just above the major G 2 -M population toward the right side of the cell distribution have phosphorylated histone H3. A region was drawn around the majority of cells with highly phosphorylated histone H3 for the untreated control cells at each time point, and cells in this region were classified as phophohistone H3-positive in the treated groups. The proportion of phospho-histone H3-positive G 2 -M cells is plotted in Fig. 4B as a function of time after inhibitor addition. Addition of PF-03814735 at 500 nmol/L immediately suppressed H3 histone phosphorylation in all 3 cell lines compared with untreated controls, with NCI-H345 showing slightly less sensitivity than the other two. After washing the inhibitor from the cells, histone H3 phosphorylation levels returned to control values immediately (data not shown). Despite the return to pretreatment phosphorylation levels, NCI-H82 and NCI-H69 cells had protracted disruption of their cell cycles, with significant arrest in G 2 -M and accumulation of polyploid (>4N DNA content) cells (Fig. 4C) . The MYCand MYCN-driven cell lines NCI-H82 and NCI-H69, respectively, had higher S-phase fractions (with or without Aurora kinase inhibitor treatment) than the cell line NCI-H345 with no Myc gene activation.
PF-03814735 in vivo activity in Myc-driven SCLC xenografts
We selected 2 SCLC models sensitive in vitro to PF-03814735 inhibition, NCI-H82 and NCI-H69, for further in vivo experiments in mice; the tumorigenicity of the normal Myc expressing cell line NCI-H345 was too inconsistent for xenograft antitumor studies. Because there was lasting disruption of cell cycle after washout in vitro, we compared intermittent dosing with daily administration in vivo. Figure 5A and B show the effect of PF-03814735 on MYC-driven NCI-H82 xenografts when administered on 2 different treatment schedules: one dose twice daily once weekly Â 3, and one dose twice daily Â 10, respectively. PF-03814735 was much more effective in NCI-H82 xenografts when administered on a weekly dosing schedule at 80 mg/kg compared with a daily schedule at 15 mg/kg. PF-03814735 delayed growth by 23.5 days on the weekly schedule, which corresponds to 0.9 logs of net cell kill during the course of treatment. The antitumor efficacy against the NCI-H69 model was modest and was not schedule dependent (Fig. 5C ). The maximum tolerated dose was lower in this study (50 vs. 80 mg/kg in the H69 and H82 studies, respectively).
Discussion
We tested PF-03814735 activity in vitro in a diverse panel of lung, colon, and breast tumor lines. We found weak correlations between sensitivity and high Aurora B expression as well as low Aurora A expression. Surprisingly, SCLC lines were most sensitive. The status of several key cancer driver genes, including the Myc family and RB1 pathway members, correlated with the efficacy of PF-03814735.
One of the key effector proteins regulated by Aurora B kinase is the RB1 protein (22) (23) (24) . Nair and colleagues (24) observed that Aurora B kinase directly phosphorylates RB1 independently of cyclin-dependent kinase inhibition and CDKN2A/p16 expression, and proposed that Aurora B inhibitors activity may differ depending on the RB1 status. This functional link offers a possible explanation for the observed correlation between RB1 pathway genes and PF-03814735 sensitivity. However, in our multivariate analysis, the correlations with the RB1 pathway genes are no longer significant when the origin of cell lines is taken into account. The results of multivariate analysis are consistent with previous reports that RB1 status alone does not seem to correlate with sensitivity of preclinical models to Aurora kinase inhibitors (22, 25) . Notably, no correlation was found with the p53 status confirming previous findings with other Aurora kinase inhibitors (8, 22, 25) .
In the SCLC panel, activation via gene amplification and/or upregulated expression of Myc family genes was associated with sensitivity that is reversible upon siRNA knockdown. No obvious difference was seen between individual Myc family members, indicating a common mechanism of action, despite the fact that the downstream gene expression signatures of Myc family amplifications have little overlap (26) . Indeed, analyses of MYC-and MYCN-driven models indicated common downstream consequences of Aurora B inhibition, including a decrease in phosphohistone H3 and increased cell ploidy. These findings are consistent with the molecular phenotype of PF-03814735 as well as other AURKB inhibitors (6, 7, 10, 23) .
In a MYC-driven model NCI-H82, PF-03814735 was more effective when administered on a weekly dosing schedule at 80 mg/kg compared with a daily schedule at 15 mg/kg. One explanation is that more complete target inhibition causes lasting damage to cell-cycle progression, as seen in washout experiments in vitro. This contrasts with the results obtained with the MYCN xenografts and with previous xenograft data that showed no schedule dependence (10) . One implication might be the possibility to reduce the dosing frequency in patients with Myc-driven malignancies. It is not clear why the in vivo sensitivity of the MYCN expressor NCI-H69 did not match its relative sensitivity observed in vitro.
What is the mechanism of selective sensitivity of Myc family-driven tumors to PF-03814735? One possibility is direct transcriptional regulation of Aurora gene expression by Myc-Max complexes. Indeed, AURKA and AURKB transcripts as well as protein levels are highly elevated in Myc-driven B-cell lymphomas in both mice and humans (8). The interplay between AURKA and MYCN is more complex in neuroblastoma: AURKA expression is correlated with MYCN amplification in neuroblastoma (27) , and AURKA protects the MYCN protein from degradation (21) . Recently, Faisal and colleagues (28) provided additional evidence that AURKA regulates MYCN protein levels in neuroblastoma cells through an inhibitory phosphorylation of GSK3b. AURKA inhibition decreased the activity of proproliferative signaling pathways, including MYC signaling, in medulloblastoma lines (29) . These findings suggest direct links between Myc and Aurora proteins. However, neither PF-03814735 inhibition nor siRNA knockdown of both AURKA and AURKB had any effect on MYC expression in the MYC-amplified SCLC line NCI-H82, suggesting that tissue-specific differences exist. Moreover, when we compared mRNA expression levels of all Aurora family members with PF-03814735 activity, we found no significant correlation for AURKB and a weak negative correlation between AURKA mRNA expression and sensitivity.
Interestingly, Myc family activation and Aurora B inhibition share common characteristics in their propensity to endomitosis and increased cell ploidy. MYC overexpression uncouples DNA replication from mitosis and leads to polyploidy (30) . AURKB inhibition is accompanied by increased ploidy via direct phosphorylation of the RB1 protein (23) (24) 31) . Thus the propensity to increase copy number may represent the Achilles heel of Mycdriven tumors and represent a therapeutic opportunity for Aurora B inhibitors.
Recently, Yang and colleagues (25) showed that the AURKB inhibitor VX-680 selectively kills cells that overexpress MYC. This synthetic lethal interaction is linked to disabling of the chromosomal passenger protein complex and DNA replication in the absence of cell division. The resulting polyploid cells undergo sequential apoptosis and autophagy. These results, as well as those published by den Hollander and colleagues (8) along with those presented here, suggest that Myc-driven malignancies may be a suitable target for treatment with AURKB inhibitors. Potential indications include neuroblastoma, B-cell lymphomas, SCLC, as well as other tumor indications in which patients with activation of Myc genes can be selected.
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